Dr Edward Earl Leonard Ii, MD | |
1200 116th Ave Ne, Suite D, Bellevue, WA 98004-3802 | |
(425) 455-8248 | |
(425) 462-1643 |
Full Name | Dr Edward Earl Leonard Ii |
---|---|
Gender | Male |
Speciality | Infectious Disease |
Experience | 30 Years |
Location | 1200 116th Ave Ne, Bellevue, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407874795 | NPI | - | NPPES |
1117035 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RI0200X | Internal Medicine - Infectious Disease | 00033910 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Overlake Hospital Medical Center | Bellevue, WA | Hospital |
Evergreenhealth Medical Center | Kirkland, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Overlake Medical Clinics Llc | 7012808827 | 350 |
News Archive
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.
Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.
Salt restriction in the normal diet has come under debate. While scientists are questioning the complex role of sodium in the body and the need for salt restriction, surveys have found that dietary sodium has not gone down well in large populations despite awareness on the risks of too much salt intake.
More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformite Europeenne) for the Abbott ARCHITECT HbA1c (IA) Assay.
Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 1 days ago
Entity Name | Overlake Medical Clinics Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801828421 PECOS PAC ID: 7012808827 Enrollment ID: O20040322001533 |
News Archive
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.
Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.
Salt restriction in the normal diet has come under debate. While scientists are questioning the complex role of sodium in the body and the need for salt restriction, surveys have found that dietary sodium has not gone down well in large populations despite awareness on the risks of too much salt intake.
More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformite Europeenne) for the Abbott ARCHITECT HbA1c (IA) Assay.
Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Edward Earl Leonard Ii, MD 1200 116th Ave Ne, Suite D, Bellevue, WA 98004-3802 Ph: (425) 455-8248 | Dr Edward Earl Leonard Ii, MD 1200 116th Ave Ne, Suite D, Bellevue, WA 98004-3802 Ph: (425) 455-8248 |
News Archive
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to scientific advancements in analgesia, announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for lower dose submicron indomethacin, a non-steroidal anti-inflammatory drug, for the proposed indication of treatment of mild to moderate acute pain in adults.
Chelsea Therapeutics International, Ltd. announced confirmation by the U.S. Food and Drug Administration (FDA) that its proposed Phase II protocol for CH-4051 in rheumatoid arthritis has been approved by the agency.
Salt restriction in the normal diet has come under debate. While scientists are questioning the complex role of sodium in the body and the need for salt restriction, surveys have found that dietary sodium has not gone down well in large populations despite awareness on the risks of too much salt intake.
More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced today CE Marking (Conformite Europeenne) for the Abbott ARCHITECT HbA1c (IA) Assay.
Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 1 days ago
Joseph W Doucette, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite 600, Bellevue, WA 98004 Phone: 425-454-2656 Fax: 425-990-5261 | |
Roanne R E Selinger, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, #560, Bellevue, WA 98004 Phone: 425-454-4768 Fax: 425-462-8021 | |
Patsy C Lazarous, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 Fax: 844-620-1839 | |
Dr. Patricia Martin, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1407 116th Ave Ne, Suite 200, Bellevue, WA 98004 Phone: 425-454-5046 Fax: 425-990-5261 | |
Dr. Rahil Barketali Roopani, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1800 116th Ave Ne Ste 102, Bellevue, WA 98004 Phone: 425-947-9485 Fax: 425-977-9034 | |
David C Morton, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite 110a, Bellevue, WA 98004 Phone: 425-289-3100 Fax: 425-289-3103 | |
Shie-pon Tzung, MD PHD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, #560, Bellevue, WA 98004 Phone: 425-454-4768 Fax: 425-462-8021 |